| Name | Title | Contact Details |
|---|---|---|
Mike Tomasco |
Senior Vice President - Chief Information Officer | Profile |
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
Geltor is the bio-design company that makes the world`s most advanced proteins for consumers, with a focus on unique functionality and sustainability.
Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders
NeuroVista Corporation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Adventus Group is a Freeport, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.